Maralixibat

  • TRADE NAME: Livmarli (Mirum Pharma)
  • INDICATIONS: Treatment of cholestatic pruritus in patients with Alagille syndrome. 
  • CLASS: Bile acid transporter inhibitor
  • HALF-LIFE: 1.6 hours

FDA APPROVAL DATE: 09/28/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Bile acid binding resins, Cholestyramine, Statins


Maternal use at the recommended clinical dose of maralixibat is not expected to result in measurable fetal exposure because systemic absorption following oral administration is low.

Our database has 24 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OTIC.
RESPIRATORY.


Page last updated 09/24/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top